BACKGROUND: Whereas the incidence, risk factors, and clinical sequelae of herpes zoster have been studied in the general population and in HIV patients in the era before highly active antiretroviral therapy (HAART), they have yet to be fully understood in the current era of HAART. METHODS: We conducted a retrospective cohort study of patients enrolled in an urban HIV clinic between January 1, 1997 and December 31, 2001. Patients with an episode of herpes zoster during this period were identified, and their charts were reviewed. A nested case-control analysis was used to assess factors associated with an initial episode of herpes zoster. Multivariate conditional logistic regression analyses were used to assess risk factors for zoster. Logistic regression was performed to assess factors associated with complicated zoster. RESULTS: Two hundred eighty-two episodes of herpes zoster were identified in 239 patients. Of these episodes, 158 were new occurrences of zoster and 124 were recurrent zoster events. The incidence of zoster during the study period was 3.2 per 100 person-years of follow-up. The incident cases reflected the clinic population, with most patients being male (63%) and African American (77%) and having injection drug use as their HIV risk factor (49%). The mean age of the patients was 41 years. Sixty-seven percent of patients had single dermatomal involvement, and the thorax was involved in 41%. In multivariate regression, being on HAART (odds ratio [OR] = 2.39, 95% confidence interval [CI]: 1.65 to 3.49) and a CD4 count of 50 to 200 cells/mm (OR = 2.69, 95% CI: 1.44 to 5.01) compared with a CD4 count less than 50 cells/mm were associated with an increased risk of zoster. Twenty-eight patients (18%) developed post-herpetic neuralgia (PHN), and 29 patients (18%) had other complications. Male-to-male sex as an HIV risk factor (P = 0.02) and being on HAART at a zoster episode (P = 0.03) were protective against complicated zoster. CONCLUSIONS: Our results suggest that zoster infection rates have not changed in the current HAART era but that a significant percentage of patients develop complications, particularly PHN, which is quite remarkable considering the young age of our population.
BACKGROUND: Whereas the incidence, risk factors, and clinical sequelae of herpes zoster have been studied in the general population and in HIV patients in the era before highly active antiretroviral therapy (HAART), they have yet to be fully understood in the current era of HAART. METHODS: We conducted a retrospective cohort study of patients enrolled in an urban HIV clinic between January 1, 1997 and December 31, 2001. Patients with an episode of herpes zoster during this period were identified, and their charts were reviewed. A nested case-control analysis was used to assess factors associated with an initial episode of herpes zoster. Multivariate conditional logistic regression analyses were used to assess risk factors for zoster. Logistic regression was performed to assess factors associated with complicated zoster. RESULTS: Two hundred eighty-two episodes of herpes zoster were identified in 239 patients. Of these episodes, 158 were new occurrences of zoster and 124 were recurrent zoster events. The incidence of zoster during the study period was 3.2 per 100 person-years of follow-up. The incident cases reflected the clinic population, with most patients being male (63%) and African American (77%) and having injection drug use as their HIV risk factor (49%). The mean age of the patients was 41 years. Sixty-seven percent of patients had single dermatomal involvement, and the thorax was involved in 41%. In multivariate regression, being on HAART (odds ratio [OR] = 2.39, 95% confidence interval [CI]: 1.65 to 3.49) and a CD4 count of 50 to 200 cells/mm (OR = 2.69, 95% CI: 1.44 to 5.01) compared with a CD4 count less than 50 cells/mm were associated with an increased risk of zoster. Twenty-eight patients (18%) developed post-herpetic neuralgia (PHN), and 29 patients (18%) had other complications. Male-to-male sex as an HIV risk factor (P = 0.02) and being on HAART at a zoster episode (P = 0.03) were protective against complicated zoster. CONCLUSIONS: Our results suggest that zoster infection rates have not changed in the current HAART era but that a significant percentage of patients develop complications, particularly PHN, which is quite remarkable considering the young age of our population.
Authors: Kate Shearer; Mhairi Maskew; Toyin Ajayi; Rebecca Berhanu; Pappie Majuba; Ian Sanne; Matthew P Fox Journal: Int J Infect Dis Date: 2014-03-25 Impact factor: 3.623
Authors: Kosuke Kawai; Claudia A Hawkins; Ellen Hertzmark; Joel M Francis; David Sando; Aisa N Muya; Nzovu Ulenga; Wafaie W Fawzi Journal: Am J Trop Med Hyg Date: 2018-01-04 Impact factor: 2.345
Authors: Constance A Benson; Janet W Andersen; Bernard J C Macatangay; Robbie B Mailliard; Charles R Rinaldo; Sarah Read; Dawn R Bozzolo; Lynette Purdue; Cheryl Jennings; Michael C Keefer; Marshall Glesby; Pablo Tebas; Amy Falk Russell; Jason Martin; Paula Annunziato; Zoran Popmihajlov; Jeffrey L Lennox Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 9.079
Authors: Ruanne V Barnabas; Jared M Baeten; Jairam R Lingappa; Katherine K Thomas; James P Hughes; Nelly R Mugo; Sinead Delany-Moretlwe; Glenda Gray; Helen Rees; Andrew Mujugira; Allan Ronald; Wendy Stevens; Saidi Kapiga; Anna Wald; Connie Celum Journal: J Infect Dis Date: 2015-06-08 Impact factor: 5.226
Authors: Henry Masur; John T Brooks; Constance A Benson; King K Holmes; Alice K Pau; Jonathan E Kaplan Journal: Clin Infect Dis Date: 2014-02-27 Impact factor: 9.079
Authors: Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High Journal: Clin Infect Dis Date: 2008-08-15 Impact factor: 9.079
Authors: Huifeng Yun; Shuo Yang; Lang Chen; Fenglong Xie; Kevin Winthrop; John W Baddley; Kenneth G Saag; Jasvinder Singh; Jeffrey R Curtis Journal: Arthritis Rheumatol Date: 2016-09 Impact factor: 10.995